Direct electrochemistry of Heme Proteins on Electrodes Modified with Didodecyldimethyl Ammonium Bromide and Carbon Black

A novel matrix based on commercially available carbon black (CB) N220 and didodecyldimethyl ammonium bromide (DDAB) was shown to be a reliable support for direct electron transfer reactions between screen printed electrode (SPE) and Fe(III)-heme proteins. Cytochrome c(cytc), myoglobin (Mb), horseradish peroxidase (HRP) and cytochromes P450 (CYP 51A1, CYP 3A4, CYP 2B4) generated well-shaped cyclic voltammograms on SPE/CB/ DDAB electrodes (both in solution and in immobilized state). The attractive performance characteristics of CB modified electrodes are advantageous over single-walled carbon nanotubes (SW CNT) based ones. The achieved direct electrochemistry of heme proteins on CB/DDAB-modified electrodes provided successful elaboration of the immunosensor for cardiac Mb. The immunosensor showed applicability for diagnostics of myocardial infarction displaying significant difference in cardiac Mb content of human blood plasma samples taken from the corresponding patients

Индивидуальная оценка уровня простатического специфического антигена у больных раком предстательной железы после брахитерапии

The study covered 44 patients with localized and locally advanced prostate cancer (PC), who were followed up for at least 18 months after brachytherapy. A significant reduction in the level of prostatic specific antigen (PSA) in the blood of patients was observed 3 months after brachytherapy and tended to decrease further during a 12-month follow-up. It is the time after brachytherapy that may be considered as a criterion for a primary tumor response to the therapy. There were individual differences in the velocity and decrease rate of PSA levels during the therapy: in 30 (68.2%) patients, PSA values were in the range of 0.01—0.98 ng/ml (mean 0.39±0.31 ng/ml) while in 14 (31.8%) patients, those were 1.10—6.20 ng/ml (3.02±1.79 ng/ml). A certain correlation was found between the parameters of PSA (baseline PSA level, time course of changes, and kinetics of PSA levels) and the outcome of the disease. A more objective evaluation of the efficiency may be made after increasing the time of a follow-up and the number of patients after brachytherapy.

Флюоресцентная гибридизация in situ: практическое применение в онкоурологии

Tumor markers for diagnosis of bladder cancer and defining the prognosis of the disease have been actively studied for past decade. FISH-study demonstrates the highest sensitivity and specificity. Abbot Company has developed a diagnostic test system «UroVision» which includes colored DNA-probes referring to 3, 7, 17 and 9p21 chromosomes. This system use provides clinicians with insights into an early diagnosis, prognosis and monitoring of efficacy of anticancer therapy.

Зомета в терапии рака предстательной железы с метастатическим поражением костей на фоне андрогенной депривации (результаты Российского многоцентрового исследования)

Introduction: Hormonal therapy is the method of choice in treating disseminated prostate cancer. Chronic androgenic suppression causes a reduction in bone mineral density. The most common complications of bone metastases are pathological fractures, spinal cord compression, pain, etc.Methods: A multicenter study (11 clinics of Russia) assessing the efficacy of Zometa in preventing skeletal complications of bone metastases was conducted in 2004—2005. Zometa was administered intravenously at a dose of 4 mg every 3Р4 weeks with androgenic deprivation. Its objective effect was evaluated in 70 patients. Changes in bone mineral density were evaluated by densitometry.Results: Complete pain relief was achieved in 73% of the patients; after therapy 86% of the patients had 0—1 WHO activity status score, 97% of the patients had no bone complications. The level of bone resorption marker β-Cross-Laps decreased to the normal values in 51% of the patients.Conclusion: The study has provided an evidence of the efficacy of Zometa and the necessity of using this drug in complex therapy for bone metastases of prostate cancer.Introduction: Hormonal therapy is the method of choice in treating disseminated prostate cancer. Chronic androgenic suppression causes a reduction in bone mineral density. The most common complications of bone metastases are pathological fractures, spinal cord compression, pain, etc.Methods: A multicenter study (11 clinics of Russia) assessing the efficacy of Zometa in preventing skeletal complications of bone metastases was conducted in 2004—2005. Zometa was administered intravenously at a dose of 4 mg every 3Р4 weeks with androgenic deprivation. Its objective effect was evaluated in 70 patients. Changes in bone mineral density were evaluated by densitometry.Results: Complete pain relief was achieved in 73% of the patients; after therapy 86% of the patients had 0—1 WHO activity status score, 97% of the patients had no bone complications. The level of bone resorption marker β-Cross-Laps decreased to the normal values in 51% of the patients.Conclusion: The study has provided an evidence of the efficacy of Zometa and the necessity of using this drug in complex therapy for bone metastases of prostate cancer

Individual estimation of the level of prostatic specific antigen in patients with prostate cancer after brachytherapy

The study covered 44 patients with localized and locally advanced prostate cancer (PC), who were followed up for at least 18 months after brachytherapy. A significant reduction in the level of prostatic specific antigen (PSA) in the blood of patients was observed 3 months after brachytherapy and tended to decrease further during a 12-month follow-up. It is the time after brachytherapy that may be considered as a criterion for a primary tumor response to the therapy. There were individual differences in the velocity and decrease rate of PSA levels during the therapy: in 30 (68.2%) patients, PSA values were in the range of 0.01—0.98 ng/ml (mean 0.39±0.31 ng/ml) while in 14 (31.8%) patients, those were 1.10—6.20 ng/ml (3.02±1.79 ng/ml). A certain correlation was found between the parameters of PSA (baseline PSA level, time course of changes, and kinetics of PSA levels) and the outcome of the disease. A more objective evaluation of the efficiency may be made after increasing the time of a follow-up and the number of patients after brachytherapy

Fluorescent in situ hybridization: clinical use in oncourology

Tumor markers for diagnosis of bladder cancer and defining the prognosis of the disease have been actively studied for past decade. FISH-study demonstrates the highest sensitivity and specificity. Abbot Company has developed a diagnostic test system «UroVision» which includes colored DNA-probes referring to 3, 7, 17 and 9p21 chromosomes. This system use provides clinicians with insights into an early diagnosis, prognosis and monitoring of efficacy of anticancer therapy

Conducting polymers from aminobenzoic acids and aminobenzenesulphonic acids: influence of pH on electrochemical behaviour

The influence of pH on the electrochemical behaviour of conducting polymer films electrosynthesised from aminobenzoic acids and aminobenzenesulphonic acids was investigated by voltammetric and electrochemical impedance studies in sulphuric acid solution, acetate buffer and neutral phosphate buffer. The change in electrochemical behaviour with increasing pH is significantly less for poly(aminobenzenesulphonic acid)s and poly(aminobenzoic acid)s than for polyaniline. Polymer films made by electrosynthesis of mixtures of these monomers with aniline have also been analysed by the same techniques. Experimental results obtained over this pH range are interpreted in the light of previous studies carried out on these polymers in strong acid solution.http://www.sciencedirect.com/science/article/B6TGB-479KCT3-2/1/996537b5327d9ca5219aa836e384a17